跳至主要内容
临床试验/EUCTR2004-002855-15-IT
EUCTR2004-002855-15-IT进行中(未招募)不适用

A long term extension to a randomised, double-blind, placebo-controlled, stratified, paralle-group, multicenter, dose-ranging study evaluating four oral doses of TCH346 1.0, 2.5, 7.5 and 15 mg administered once daily in patients with Amyotrophic Lateral Sclerosis

OVARTIS FARMA0 个研究点目标入组 476 人开始时间: 2007年1月8日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
OVARTIS FARMA
入组人数
476

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 未提供

研究者

发起方
OVARTIS FARMA

相似试验

进行中(未招募)
不适用
A long-term extension to a randomized, double-blind, placebo-controlled, stratified, parallel-group, multicenter, dose-ranging study evaluating four oral doses of TCH346 (1.0, 2.5, 7.5 and 15mg) administered once daily in patients with Amyotrophic Lateral Sclerosis.Amyotrophic Lateral Sclerosis
EUCTR2004-002855-15-DEovartis Pharma Services AG480
进行中(未招募)
不适用
A long-term extension to a randomized, double-blind, placebo-controlled, stratified, parallel-group, multicenter, dose-ranging study evaluating four oral doses of TCH346 (1.0, 2.5, 7.5 and 15mg) administered once daily in patients with Amyotrophic Lateral Sclerosis.Amyotrophic Lateral Sclerosis
EUCTR2004-002855-15-GBovartis Pharma Services AG480
进行中(未招募)
3 期
REVEAL 1 (Randomized Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)Cervical DysplasiaCervical High Grade Squamous Intraepithelial LesionHSI
TCTR20170301001Inovio Pharmaceuticals, Inc.201
进行中(未招募)
不适用
A LONG-TERM, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP,PLACEBO-CONTROLLED, RADIOGRAPHIC STUDY TO INVESTIGATE THESAFETY AND EFFICACY OF ORALLY ADMINISTERED SD-6010 IN SUBJECTSWITH SYMPTOMATIC OSTEOARTHRITIS OF THE KNEEOsteoarthritis
EUCTR2007-001457-26-CZPfizer Inc, 235 East 42nd Street, New York, NY 100171,400
进行中(未招募)
不适用
A LONG-TERM, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, RADIOGRAPHIC STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF ORALLY ADMINISTERED SD-6010 IN SUBJECTS WITH SYMPTOMATIC OSTEOARTHRITIS OF THE KNEE - NDOsteoarthritis
EUCTR2007-001457-26-ITPFIZER1,400
A long term extension to a randomised, double-blind,... | 临床试验